Literature DB >> 21946808

Synthesis and biological activity of optimized belactosin C congeners.

Vadim S Korotkov1, Antje Ludwig, Oleg V Larionov, Alexander V Lygin, Michael Groll, Armin de Meijere.   

Abstract

Successful biochemical studies of the natural products belactosin A and C as well as their more stable acylated derivatives have proved them to be powerful proteasome inhibitors and thereby potential candidates as pharmacologically relevant active compounds. In order to understand their structure-biological activity relations in detail and to find ways of improving their biological activity, four new modified belactosin congeners have been synthesized and tested. One of them (compound 6) turned out to be a more potent inhibitor against HeLa cells than the known proteasome inhibitor MG132.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946808     DOI: 10.1039/c1ob05661a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  3 in total

1.  Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis.

Authors:  Bernd Hewing; Antje Ludwig; Cristian Dan; Max Pötzsch; Carmen Hannemann; Andreas Petry; Dilyara Lauer; Agnes Görlach; Elena Kaschina; Dominik N Müller; Gert Baumann; Verena Stangl; Karl Stangl; Nicola Wilck
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

2.  Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.

Authors:  Grace E Hubbell; Jetze J Tepe
Journal:  RSC Chem Biol       Date:  2020-09-16

3.  Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents.

Authors:  Carlos R Viera; Bradley T Stevens; Talysa Viera; Cameron Zielinski; Lee A Uranga; Snezna Rogelj; Praveen L Patidar; Rodolfo Tello-Aburto
Journal:  R Soc Open Sci       Date:  2022-09-28       Impact factor: 3.653

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.